The company had been working to expand its retrospective data over the last year and half and is now readying to move forward with prospective studies.
Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.
The companies said Tuesday that they are pursuing a clinical trial utilizing their respective liquid biopsy assays on clinical samples from lung cancer patients.
Bluestar hopes to launch a pan-cancer, DNA methylation-based liquid biopsy assay as a laboratory-developed test out of an envisioned CLIA-certified lab in San Diego.
Researchers linked chromatin interactions, super-interactive promoters, and other regulatory features to specific cell types in the developing brain cortex.
Investigators identified disease-associated histone modifications in the brain that appeared to influence transcription- and chromatin-related processes.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
